Is Advanced Enzyme Technologies the Best Stock in Its Sector? A Look at the Numbers
- September 16, 2026
- Posted by: Harsh Piplani
- Category: Market
Advanced Enzyme Technologies CMP Rs 288 (16 Sep 2026). Market cap Rs 3,232 Cr. ROE 10.34%. P/E 18.81x versus Industry P/E 37.96x.
Quick Answer
Advanced Enzyme Technologies is one of the names investors compare when screening the Healthcare sector, built on a 10.34% return on equity and a P/E of 18.81x against an Industry P/E of 37.96x. Whether Advanced Enzyme Technologies is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Healthcare sector peers, so you can judge that for yourself.
Is Advanced Enzyme Technologies the best stock in its sector? The stock trades on the NSE at Rs 288 as of 16 September 2026, within its 52-week range of Rs 251.95 to Rs 419.00. Advanced Enzyme Technologies Ltd manufactures specialty enzymes for pharmaceutical, nutraceutical, food and animal feed applications.
Advanced Enzyme Technologies sits in the Healthcare sector, and its 10.34% ROE and 18.81x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Advanced Enzyme Technologies
Advanced Enzyme Technologies Ltd manufactures specialty enzymes for pharmaceutical, nutraceutical, food and animal feed applications. It manufactures specialty enzymes used in pharmaceutical, nutraceutical, food and animal feed applications, a more specialised niche than generic formulation manufacturing. At a market capitalisation of Rs 3,232 Cr, it is tracked as part of the Healthcare sector on Univest.
Is Advanced Enzyme Technologies the Best Stock in Its Sector?
Advanced Enzyme Technologies makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 10.34% ROE with a 18.81x P/E against the sector’s 37.96x Industry P/E. Advanced Enzyme Technologies’ 18.81x P/E is well below the 37.96x Industry P/E, with a 10.34% ROE that trails Bajaj Healthcare and Alembic Pharmaceuticals in this series, reflecting its specialty enzyme niche rather than volume formulation manufacturing.
| Metric | Advanced Enzyme Technologies |
|---|---|
| CMP (NSE) | Rs 287.85 |
| 52-Week High / Low | Rs 419.00 / Rs 251.95 |
| Market Cap | Rs 3,232 Cr |
| P/E (TTM) vs Industry P/E | 18.81x vs 37.96x |
| P/B | 1.98 |
| ROE | 10.34% |
| EPS (TTM) | Rs 15.34 |
| Dividend Yield | 1.85% |
| Debt to Equity | 0.02 |
Compare Advanced Enzyme Technologies Against Other Healthcare Sector Stocks
How Advanced Enzyme Technologies Compares Against Its Healthcare Sector Peers
The table below sets Advanced Enzyme Technologies against 3 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 3 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Advanced Enzyme Technologies | 3,232 | 18.81 | 10.34% | 0.02 |
| Bajaj Healthcare | 1,125 | 63.76 | 8.81% | 0.47 |
| Alembic Pharmaceuticals | 15,964 | 23.15 | 11.89% | 0.25 |
| Sai Life Sciences | 32,723 | 90.47 | 14.05% | 0.12 |
| Peer average (3 companies) | – | 59.13 | 11.58% | 0.28 |
Against this peer set, Advanced Enzyme Technologies’s 10.34% ROE is below the 11.58% peer average, and its P/E of 18.81x runs below the peer average of 59.13x. Advanced Enzyme Technologies’ 18.81x P/E is well below the 37.96x Industry P/E, with a 10.34% ROE that trails Bajaj Healthcare and Alembic Pharmaceuticals in this series, reflecting its specialty enzyme niche rather than volume formulation manufacturing.
What Makes Advanced Enzyme Technologies Worth Watching in Healthcare
- Well below Industry P/E: An 18.81x P/E against a 37.96x Industry P/E is a wide discount for a specialty enzymes manufacturer.
- Near debt free: A debt to equity ratio of 0.02 gives Advanced Enzyme Technologies flexibility to invest in R&D and capacity.
- Specialty enzyme niche: Focusing on specialty enzymes for pharma, nutraceutical and food applications differentiates it from generic pharma manufacturers.
Advanced Enzyme Technologies Valuation: Is It Justified?
Advanced Enzyme Technologies’ 18.81x P/E is well below the 37.96x Industry P/E, with a 10.34% ROE that trails Bajaj Healthcare and Alembic Pharmaceuticals in this series, reflecting its specialty enzyme niche rather than volume formulation manufacturing. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Bata India the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Advanced Enzyme Technologies and other Healthcare sector stocks.
How to Track Advanced Enzyme Technologies Before You Invest
Before deciding whether Advanced Enzyme Technologies deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.
- Open the Univest Screener and search for Advanced Enzyme Technologies to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
- Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Advanced Enzyme Technologies earns a place in the best stock in its sector conversation on the strength of a 10.34% ROE and a P/E of 18.81x against a 37.96x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Advanced Enzyme Technologies the best stock in its sector?
Ans. Advanced Enzyme Technologies has a 10.34% ROE and trades at 18.81x P/E against a 37.96x Industry P/E, and compares below the peer average ROE of 11.58% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Advanced Enzyme Technologies?
Ans. Advanced Enzyme Technologies was trading at Rs 287.85 on the NSE as of 16 September 2026, within its 52-week range of Rs 251.95 to Rs 419.00.
What sector does Advanced Enzyme Technologies belong to?
Ans. Advanced Enzyme Technologies is classified under the Healthcare sector on Univest.
How does Advanced Enzyme Technologies compare to its sector peers on P/E?
Ans. Advanced Enzyme Technologies’s P/E of 18.81x is below the 59.13x average of the 3 named peers compared in this article.
What is Advanced Enzyme Technologies’s return on equity?
Ans. Advanced Enzyme Technologies reported a return on equity of 10.34%, which is below the 11.58% average of its named peers in this comparison.
Should I invest in Advanced Enzyme Technologies based on its sector position?
Ans. Advanced Enzyme Technologies’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
